secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001641172-25-020042
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 reverses STAT1 epigenetic silencing in prostate cancer, outperforming Paclitaxel and Rapamycin
--------------------------------------------------------------------------------

- In PC3 xenograft model, Telomir-1 fully reversed STAT1 hypermethylation after 21-day oral daily dosing.
- No STAT1 reversal was seen with Paclitaxel; only partial demethylation was observed with Rapamycin.
- Telomir-1 also reduced TMS1 hypermethylation, a pro-apoptotic tumor suppressor involved in immune signaling.
- Telomere length in tumor tissue was not elongated, addressing a key safety concern for telomere-targeting compounds.
- Company is advancing Telomir-1 toward IND filing and evaluating it in Wilson's disease, AMD, autism, and dysphonia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225020042/0001641172-25-020042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225020042/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-020042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer